Scientists identify Buphenyl as a possible drug for Alzheimer's disease

March 11, 2013

(Medical Xpress)—Buphenyl, an FDA-approved medication for hyperammonemia, may protect memory and prevent the progression of Alzheimer's disease. Hyperammonemia is a life-threatening condition that can affect patients at any age. It is caused by abnormal, high levels of ammonia in the blood.

Studies in mice with Alzheimer's disease (AD) have shown that sodium phenylbutyrate, known as Buphenyl, successfully increases factors for neuronal growth and protects , according to neurological researchers at the Rush University Medical Center.

Results from the National Institutes of Health funded study, recently were published in the .

"Understanding how the disease works is important to developing effective drugs that protect the brain and stop the progression of Alzheimer's disease," said Kalipada Pahan, PhD, the Floyd A. Davis professor of neurology at Rush and lead investigator of this study.

A family of proteins known as neurotrophic factors help in survival and function of neurons. Past research indicates that these proteins are drastically decreased in the brain of patients with Alzheimer's disease (AD).

" proteins could be increased in the brain by direct injection or ," said Pahan. "However, using an to increase the level of these protein may be the best clinical option and a cost effective way to increase the level of these proteins directly in the brain."

"Our study found that after oral feeding, Buphenyl enters into the brain, increases these beneficial , protects neurons, and improves memory and learning in mice with AD-like pathology," said Pahan.

In the brain of a patient with AD, two abnormal structures called plaques and tangles are prime suspects in damaging and killing . While neurons die, other like astroglia do not die.

The study findings indicate that Buphenyl increases neurotrophic factors from astroglia. Buphenyl stimulates memory-related protein CREB (cyclic AMP response element-binding protein) using another protein known as Protein Kinase C (PKC) and increases neurotrophic factors in the brain.

"Now we need to translate this finding to the clinic and test Buphenyl in Alzheimer's disease patients," said Pahan. "If these results are replicated in Alzheimer's disease patients, it would open up a promising avenue of treatment of this devastating neurodegenerative disease."

Other researchers involved in this study are Grant Corbett, neuroscience graduate student at Rush and Avik Roy, research assistant professor at Rush.

Alzheimer's disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest tasks. In most people with Alzheimer's, symptoms first appear after age 60. Alzheimer's disease is the most common cause of dementia among older people. Alzheimer's disease affects as many as 5.3 million Americans.

Explore further: Cholesterol drug shows benefit in animal study of Alzheimer's disease

Related Stories

Cholesterol drug shows benefit in animal study of Alzheimer's disease

April 3, 2012
A cholesterol drug commonly prescribed to reduce cardiovascular disease risk restores blood vessel function in a mouse model of Alzheimer's disease, according to a study in the April 4 issue of The Journal of Neuroscience. ...

Scientists identify mechanism that could contribute to problems in Alzheimer's

April 26, 2012
Scientists at the Gladstone Institutes have unraveled a process by which depletion of a specific protein in the brain contributes to the memory problems associated with Alzheimer's disease. These findings provide new insights ...

Purpose in life may protect against harmful changes in the brain associated with Alzheimer's disease

May 7, 2012
Greater purpose in life may help stave off the harmful effects of plaques and tangles associated with Alzheimer's disease, according to a new study by researchers at Rush University Medical Center. The study, published in ...

Recommended for you

Lifestyle changes to stave off Alzheimer's? Hints, no proof

July 20, 2017
There are no proven ways to stave off Alzheimer's, but a new report raises the prospect that avoiding nine key risks starting in childhood just might delay or even prevent about a third of dementia cases around the world.

Steering an enzyme's 'scissors' shows potential for stopping Alzheimer's disease

July 19, 2017
The old real estate adage about "location, location, location" might also apply to the biochemical genesis of Alzheimer's disease, according to new research from the University of British Columbia.

Brain scans may change care for some people with memory loss

July 19, 2017
Does it really take an expensive brain scan to diagnose Alzheimer's? Not everybody needs one but new research suggests that for a surprising number of patients whose memory problems are hard to pin down, PET scans may lead ...

Can poor sleep boost odds for Alzheimer's?

July 18, 2017
(HealthDay)— Breathing problems during sleep may signal an increased risk for Alzheimer's disease, a trio of studies suggests.

Hearing is believing: Speech may be a clue to mental decline

July 17, 2017
Your speech may, um, help reveal if you're uh ... developing thinking problems. More pauses, filler words and other verbal changes might be an early sign of mental decline, which can lead to Alzheimer's disease, a study suggests.

Bacteria found in Alzheimer's brains

July 17, 2017
Researchers in the UK have used DNA sequencing to examine bacteria in post-mortem brains from patients with Alzheimer's disease. Their findings suggest increased bacterial populations and different proportions of specific ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.